Finn Sawyer Access to Cancer Testing Act

This bill requires Medicare, Medicaid, and CHIP to cover advanced genetic cancer testing (like DNA/RNA sequencing and their interpretation) for patients diagnosed with cancer. It defines covered tests as next-generation sequencing performed by clinical labs and limits coverage to once per diagnosis, recurrence, or treatment monitoring. Medicare will pay 80% of the test cost (or 100% if billed under assignment), while Medicaid and CHIP must include these tests in mandatory coverage starting January 1, 2025. The bill directly affects cancer patients enrolled in these federal health programs by ensuring access to specific genetic testing without excessive out-of-pocket costs.